Western blot assays were performed to identify the presence of p53, phospho-p53, and murine double minute 2 (MDM2) isoforms in plasma samples. Densitometric analysis was used to determine the ...

The small molecules in question are ASTX029, an ERK1/2 inhibitor that has completed a phase 2 study, and ASTX295 an MDM2 antagonist that has undergone a phase 1 trial. Both candidates have ...

Merck KGaA’s protracted pursuit of SpringWorks Therapeutics may be nearing its endgame. The German drugmaker confirmed (PDF) it is in late-stage talks about buying the rare cancer biopharma for ...

In oncology, she highlighted MDM2-p53 antagonist brigimadlin, which has advanced into a pivotal trial for dedifferentiated liposarcoma, a rare cancer with limited treatment options so far ...

In a recent issue of the Clinical Journal of the American Society of Nephrology, Wu and colleagues reported on the predictive value of routine D-dimer measurements for future thromboembolic events ...

As part of this initiative, the company will exit its Dover, Ohio manufacturing site and transition away from the Dimer and Polyamides business lines. Kraton also operates a polymer manufacturing site ...

The work further revealed how an MDM2-targeted therapy could turn the anticancer protein back on, thereby extending survival in model systems. The findings were published today in Cancer Cell. In a ...

KT-253, A Novel MDM2 Degrader and p53 Stabilizer, Has Superior Potency and Efficacy Than MDM2 Small Molecule Inhibitors KT-253 is a highly potent and selective heterobifunctional degrader of the MDM2 ...

Sixty per cent of patients used vitamin K antagonist (VKA) within 7 days before randomisation. Prothrombin fragment 1+2 (F1+2), D-dimer, soluble CD40 ligand (sCD40L) and von Willebrand factor (vWF) ...